MedPointe buys Wampole in Carter-Wallace break-up
This article was originally published in Clinica
Executive Summary
An investment group, MedPointe Capital Partners, is to pay $408 million for the healthcare business of Carter-Wallace. Aside from pharmaceuticals, the healthcare business includes the Wampole Laboratories range of diagnostics products.